US equities |
NVDA $186.95 ▼-6.59% MU $697.89 ▼-12.24% TSLA $346.52 ▼-10.04% SPCX $125.68 ▼-7.53% AAPL $346.60 ▼-0.83% AMZN $258.82 ▼-2.71% META $608.46 ▼-3.42% AMD $416.86 ▼-14.71%
FinancialContent

NLS Pharmaceutics Ltd. - Warrant (NQ:NLSPW)

0.0179 UNCHANGED
Last Price Updated: 3:17 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NLS Pharmaceutics Ltd. - Warrant

< Previous 1 2 3 4 Next >
News headline image
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
News headline image
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Releases the Results from its Annual General Meeting
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Company Update and Webcast Today Postponed
Via ACCESSWIRE
News headline image
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Company Update Webcast
Via ACCESSWIRE
News headline image
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
Via ACCESSWIRE
News headline image
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
Via ACCESSWIRE
News headline image
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
News headline image
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy
Via ACCESSWIRE
News headline image
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)
Via ACCESSWIRE
News headline image
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
Via ACCESSWIRE
< Previous 1 2 3 4 Next >